There is not much published information on Avastin for endometrial cancer. In 2015 American Society of Clinical Oncology annual meeting a study was presented that was a phase 2 randomized trial conducted by investigators in Italy, who reported that the addition of bevacizumab (Avastin®) to carboplatin plus paclitaxel in patients with recurrent or primary advanced endometrial cancer improved both the objective response rate (72.7% vs 54.3%) and progression-free survival (median, 13.0 months vs 8.7 months; hazard ratio 0.57; P = .036) The the study was underpowered to provide a definitive answer to the question (total sample size, 108 patients) NCCN says that Avastin can be considered for patients who progressed on first line chemotherapy.
WRIGHT Jason D. et al, Bevacizumab therapy in patients with recurrent uterine neoplasms
Anticancer research ISSN 0250-7005 2007, vol. 27, no5B, pp. 3525-3528Michael Montejo et al, Current challenges in clinical management of endometrial cancer
Advanced Drug Delivery Reviews Volume 61, Issue 10, 10 August 2009, Pages 883-889
Morotti M1, Valenzano Menada M, Venturini PL, Ferrero S.Bevacizumab in endometrial cancer treatment. Expert Opin Biol Ther. 2012 May;12(5):649-58
nccn.org, endometrial ENDO-D, 1, 2017